Three areas highlight the advances made in pediatric hepatobiliary disease. First, improved understanding of risk factors for the development of hepatobiliary disease in cystic fibrosis may allow better study designs to assess the benefit of potential therapeutic interventions. Second, despite improved survival of children with biliary atresia since the introduction of orthotopic liver transplantation, its cause and factors determining the rate of progression of the cholangiopathy remain elusive. Finally, the increased use of laparoscopic cholecystectomy for targeted pediatric populations, such as those with sickle cell disease, will lead to significant benefits from reduced morbidity and cost.
© Lippincott-Raven Publishers.